Company registration number 01866803 (England and Wales)
MOLECULAR DISCOVERY LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
PAGES FOR FILING WITH REGISTRAR
PAGES FOR FILING WITH REGISTRAR
Sobell Rhodes LLP
The Kinetic Centre
Theobald Street
Elstree
Borehamwood
Hertfordshire
WD6 4PJ
MOLECULAR DISCOVERY LIMITED
COMPANY INFORMATION
Director
Mr F Cruciani
Company number
01866803
Registered office
Co Sobell Rhodes LLP
The Kinetic Centre
Theobald Street
Elstree
Borehamwood
Hertfordshire
United Kingdom
WD6 4PJ
Accountants
Sobell Rhodes LLP
The Kinetic Centre
Theobald Street
Elstree
Borehamwood
Hertfordshire
United Kingdom
WD6 4PJ
MOLECULAR DISCOVERY LIMITED
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 5
MOLECULAR DISCOVERY LIMITED
BALANCE SHEET
AS AT
31 MARCH 2025
31 March 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Intangible assets
3
-
0
1,000
Tangible assets
4
351,966
477,066
351,966
478,066
Current assets
Debtors
5
1,026,806
889,685
Cash at bank and in hand
4,736,352
5,007,971
5,763,158
5,897,656
Creditors: amounts falling due within one year
6
(571,150)
(346,847)
Net current assets
5,192,008
5,550,809
Total assets less current liabilities
5,543,974
6,028,875
Provisions for liabilities
(103,546)
(111,997)
Net assets
5,440,428
5,916,878
Capital and reserves
Called up share capital
8
5
5
Profit and loss reserves
5,440,423
5,916,873
Total equity
5,440,428
5,916,878

For the financial year ended 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

T he members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved and signed by the director and authorised for issue on 4 March 2026
Mr F Cruciani
Director
Company registration number 01866803 (England and Wales)
MOLECULAR DISCOVERY LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
- 2 -
1
Accounting policies
Company information

Molecular Discovery Limited is a private company limited by shares incorporated in England and Wales. The registered office is C/o Sobell Rhodes LLP, The Kinetic Centre, Theobald Street, Elstree, Borehamwood, Hertfordshire, WD6 4PJ .

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £1.

The financial statements have been prepared under the historical cost convention, modified to include the revaluation of certain financial instruments at fair value. The principal accounting policies adopted are set out below.

1.2
Going concern

The director has a reasonable expectation the company will continue to have adequate resources to fund its working capital for the foreseeable future. The director has carried out a detailed assessment of the viability of the company following to uncertainty over the current economic conditions due to worldwide increasing rates of inflation and interest rates. true

On the basis of the above, the director is of the opinion that there is no material uncertainty relating to going concern and therefore it is appropriate to prepare these financial statements on a going concern basis.

1.3
Turnover

The turnover shown in the profit and loss account represents licence fees invoiced during the year, exclusive of Value Added Tax.

1.4
Intangible fixed assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

Intangible assets acquired on business combinations are recognised separately from goodwill at the acquisition date where it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the fair value of the asset can be measured reliably; the intangible asset arises from contractual or other legal rights; and the intangible asset is separable from the entity.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Royalty
Over the period of 5 years
1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

MOLECULAR DISCOVERY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 3 -

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Leasehold improvements
Written off over a period of 10 years
Fixtures and fittings
25% on cost
1.6
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.

Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

1.7
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
2
2
MOLECULAR DISCOVERY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 4 -
3
Intangible fixed assets
Royalty
£
Cost
At 1 April 2024 and 31 March 2025
5,000
Amortisation and impairment
At 1 April 2024
4,000
Amortisation charged for the year
1,000
At 31 March 2025
5,000
Carrying amount
At 31 March 2025
-
0
At 31 March 2024
1,000
4
Tangible fixed assets
Land and buildings
Plant and machinery etc
Total
£
£
£
Cost
At 1 April 2024
870,723
653,834
1,524,557
Additions
48,566
-
0
48,566
At 31 March 2025
919,289
653,834
1,573,123
Depreciation and impairment
At 1 April 2024
393,657
653,834
1,047,491
Depreciation charged in the year
173,666
-
0
173,666
At 31 March 2025
567,323
653,834
1,221,157
Carrying amount
At 31 March 2025
351,966
-
0
351,966
At 31 March 2024
477,066
-
0
477,066
5
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
186,667
489,817
Corporation tax recoverable
97,845
-
0
Other debtors
35,075
15,925
Prepayments and accrued income
532,651
209,375
852,238
715,117
MOLECULAR DISCOVERY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
5
Debtors
(Continued)
- 5 -
2025
2024
Amounts falling due after more than one year:
£
£
Deferred tax asset (note )
174,568
174,568
Total debtors
1,026,806
889,685

Deferred tax assets has been provided on unrelieved tax losses of £698,272 from 2022.

6
Creditors: amounts falling due within one year
2025
2024
£
£
Trade creditors
427,335
13,782
Amounts owed to group undertakings
48,666
49,245
Taxation and social security
-
0
11,323
Other creditors
57,220
63,111
Accruals and deferred income
37,929
209,386
571,150
346,847
7
Parent and ultimate parent undertaking

The company's immediate parent is Diplema 463 Limited, incorporated in England and Wales.

8
Called up share capital
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of £1 each
5
5
5
5
9
Financial commitments, guarantees and contingent liabilities

The company has a capital commitment of £58,295 as on year end.

10
Operating Lease

The company had non-cancellable lease at the year end amounting £99,395 (2024: £136,963).

2025-03-31 2024-04-01 false false false 04 March 2026 CCH Software CCH Accounts Production 2025.300 No description of principal activity Mr F Cruciani 01866803 2024-04-01 2025-03-31 01866803 bus:Director1 2024-04-01 2025-03-31 01866803 2025-03-31 01866803 2024-03-31 01866803 core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill 2025-03-31 01866803 core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill 2024-03-31 01866803 core:LandBuildings 2025-03-31 01866803 core:OtherPropertyPlantEquipment 2025-03-31 01866803 core:LandBuildings 2024-03-31 01866803 core:OtherPropertyPlantEquipment 2024-03-31 01866803 core:CurrentFinancialInstruments 2025-03-31 01866803 core:CurrentFinancialInstruments 2024-03-31 01866803 core:ShareCapital 2025-03-31 01866803 core:ShareCapital 2024-03-31 01866803 core:RetainedEarningsAccumulatedLosses 2025-03-31 01866803 core:RetainedEarningsAccumulatedLosses 2024-03-31 01866803 core:ShareCapitalOrdinaryShareClass1 2025-03-31 01866803 core:ShareCapitalOrdinaryShareClass1 2024-03-31 01866803 core:IntangibleAssetsOtherThanGoodwill 2024-04-01 2025-03-31 01866803 core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill 2024-04-01 2025-03-31 01866803 core:LeaseholdImprovements 2024-04-01 2025-03-31 01866803 core:FurnitureFittings 2024-04-01 2025-03-31 01866803 2023-04-01 2024-03-31 01866803 core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill 2024-03-31 01866803 core:LandBuildings 2024-03-31 01866803 core:OtherPropertyPlantEquipment 2024-03-31 01866803 2024-03-31 01866803 core:LandBuildings 2024-04-01 2025-03-31 01866803 core:OtherPropertyPlantEquipment 2024-04-01 2025-03-31 01866803 core:Non-currentFinancialInstruments 2025-03-31 01866803 core:Non-currentFinancialInstruments 2024-03-31 01866803 bus:OrdinaryShareClass1 2024-04-01 2025-03-31 01866803 bus:OrdinaryShareClass1 2025-03-31 01866803 bus:OrdinaryShareClass1 2024-03-31 01866803 bus:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 01866803 bus:SmallCompaniesRegimeForAccounts 2024-04-01 2025-03-31 01866803 bus:FRS102 2024-04-01 2025-03-31 01866803 bus:AuditExemptWithAccountantsReport 2024-04-01 2025-03-31 01866803 bus:FullAccounts 2024-04-01 2025-03-31 xbrli:pure xbrli:shares iso4217:GBP